| Gregory Radin, MD | |
|
50 N Medical Dr, Salt Lake City, UT 84132-2526 | |
| (801) 581-2353 | |
| Not Available |
| Full Name | Gregory Radin |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 13 Years |
| Location | 50 N Medical Dr, Salt Lake City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275823387 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Utah Acuity Care Services | 4789908534 | 108 |
| University Of Utah Adult Services | 0941525273 | 1459 |
News Archive
Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) - a member of a family of chromatin modifying proteins - in the development of skin tumors.
Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.
The American Society of Bariatric Physicians is concerned that the FDA recently rejected the weight-loss drug Contrave, contradicting the FDA advisory panel's recommendation for approval. The rejection of Contrave marks the third weight-loss drug to be rejected by the FDA in the past six months.
Scientists of Friedrich Schiller University Jena and Jena University Hospital decode the antihypertensive impact of omega-3 fatty acids. In two newly published articles for the well-known science magazine 'Proceedings of the National Academy of Sciences, USA' they describe how they analyzed the impact of omega-3 fatty acids on a systemic level and they also described the underlying molecular mechanisms for the first time.
› Verified 7 days ago
| Entity Name | University Of Utah Acuity Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407250541 PECOS PAC ID: 4789908534 Enrollment ID: O20150127000392 |
News Archive
Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) - a member of a family of chromatin modifying proteins - in the development of skin tumors.
Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.
The American Society of Bariatric Physicians is concerned that the FDA recently rejected the weight-loss drug Contrave, contradicting the FDA advisory panel's recommendation for approval. The rejection of Contrave marks the third weight-loss drug to be rejected by the FDA in the past six months.
Scientists of Friedrich Schiller University Jena and Jena University Hospital decode the antihypertensive impact of omega-3 fatty acids. In two newly published articles for the well-known science magazine 'Proceedings of the National Academy of Sciences, USA' they describe how they analyzed the impact of omega-3 fatty acids on a systemic level and they also described the underlying molecular mechanisms for the first time.
› Verified 7 days ago
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) - a member of a family of chromatin modifying proteins - in the development of skin tumors.
Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.
The American Society of Bariatric Physicians is concerned that the FDA recently rejected the weight-loss drug Contrave, contradicting the FDA advisory panel's recommendation for approval. The rejection of Contrave marks the third weight-loss drug to be rejected by the FDA in the past six months.
Scientists of Friedrich Schiller University Jena and Jena University Hospital decode the antihypertensive impact of omega-3 fatty acids. In two newly published articles for the well-known science magazine 'Proceedings of the National Academy of Sciences, USA' they describe how they analyzed the impact of omega-3 fatty acids on a systemic level and they also described the underlying molecular mechanisms for the first time.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Radin, MD 50 N Medical Dr, Salt Lake City, UT 84132-0001 Ph: (801) 581-2353 | Gregory Radin, MD 50 N Medical Dr, Salt Lake City, UT 84132-2526 Ph: (801) 581-2353 |
News Archive
Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) - a member of a family of chromatin modifying proteins - in the development of skin tumors.
Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.
The American Society of Bariatric Physicians is concerned that the FDA recently rejected the weight-loss drug Contrave, contradicting the FDA advisory panel's recommendation for approval. The rejection of Contrave marks the third weight-loss drug to be rejected by the FDA in the past six months.
Scientists of Friedrich Schiller University Jena and Jena University Hospital decode the antihypertensive impact of omega-3 fatty acids. In two newly published articles for the well-known science magazine 'Proceedings of the National Academy of Sciences, USA' they describe how they analyzed the impact of omega-3 fatty acids on a systemic level and they also described the underlying molecular mechanisms for the first time.
› Verified 7 days ago
Dr. Mehmet Akkaya, M.D Pulmonary Disease Medicare: Medicare Enrolled Practice Location: University Of Utah Hospital Cardiology, 3o N,1900 E, Rm:4a100, Salt Lake City, UT 84132 Phone: 801-505-1689 | |
Dr. Willard Dere, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 500 Foothill Blvd, Salt Lake City, UT 84148 Phone: 801-582-1565 | |
Megan Meier, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 | |
Joel Money, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 | |
Mchale O. Anderson, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4a100, Salt Lake City, UT 84132 Phone: 801-587-2451 | |
Siddharth K. Iyengar, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4c116, Salt Lake City, UT 84132 Phone: 801-581-7606 | |
Taryn A. Young, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 5121 S Cottonwood St, Salt Lake City, UT 84107 Phone: 801-507-4384 Fax: 801-507-4398 |